- Home
- NTIP vs ENLV Comparison
NTIP vs ENLV Comparison
Compare NTIP & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- ENLV
- Stock Information
- Founded
- NTIP 1990
- ENLV 2005
- Country
- NTIP United States
- ENLV Israel
- Employees
- NTIP N/A
- ENLV N/A
- Industry
- NTIP Multi-Sector Companies
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- ENLV Health Care
- Exchange
- NTIP Nasdaq
- ENLV Nasdaq
- Market Cap
- NTIP 32.0M
- ENLV 26.6M
- IPO Year
- NTIP 1998
- ENLV 1995
- Fundamental
- Price
- NTIP $1.50
- ENLV $1.07
- Analyst Decision
- NTIP
- ENLV Strong Buy
- Analyst Count
- NTIP 0
- ENLV 2
- Target Price
- NTIP N/A
- ENLV $10.00
- AVG Volume (30 Days)
- NTIP 9.7K
- ENLV 195.3K
- Earning Date
- NTIP 10-24-2025
- ENLV 11-28-2025
- Dividend Yield
- NTIP 6.67%
- ENLV N/A
- EPS Growth
- NTIP N/A
- ENLV N/A
- EPS
- NTIP N/A
- ENLV N/A
- Revenue
- NTIP $150,000.00
- ENLV N/A
- Revenue This Year
- NTIP N/A
- ENLV N/A
- Revenue Next Year
- NTIP N/A
- ENLV N/A
- P/E Ratio
- NTIP N/A
- ENLV N/A
- Revenue Growth
- NTIP N/A
- ENLV N/A
- 52 Week Low
- NTIP $1.16
- ENLV $0.81
- 52 Week High
- NTIP $1.90
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- NTIP 46.75
- ENLV 47.29
- Support Level
- NTIP $1.48
- ENLV $1.04
- Resistance Level
- NTIP $1.54
- ENLV $1.10
- Average True Range (ATR)
- NTIP 0.04
- ENLV 0.05
- MACD
- NTIP -0.00
- ENLV -0.00
- Stochastic Oscillator
- NTIP 17.56
- ENLV 23.36
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.